Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Spyre Therapeutics, Inc. Banner

Spyre Therapeutics, Inc.

SYRE Stock Analysis

Page title

Section title

Breakdown
2016
2017
2018
2019
2020
2021
2022
2023
Net Income
-21.698m-27.236m-44.348m-78.254m-80.893m-65.801m-83.815m-338.790m
Depreciation & Amortization
132.000K249.000K293.000K901.000K996.000K1.576M1.567M744.000K
Change in Working Capital
1.450M-198.000k7.201M7.104M-2.540m1.833M-5.503m-5.206m
Operating Cash Flow
-18.840m-24.615m-32.193m-65.692m-75.775m-53.716m-80.144m-99.910m
Capital Expenditure
-212.000k-619.000k-422.000k-1.492m-4.280m-573.000k-38.000k0.000
Free Cash Flow
-19.052m-25.234m-32.615m-67.184m-80.055m-54.289m-80.182m-99.910m
Debt Repayment
0.0000.0000.000-25.000k-20.000k-510.000k-418.000k-16.000k
Dividends Paid
0.0000.0000.0000.0000.0000.0000.0000.000
Common Stock Issued
49.370M12.213M57.068M65.748M153.716M1.903M42.874M169.110M
Common Stock Repurchased
0.0000.0000.0000.0000.0000.0000.0000.000
Net Change in Cash
18.374M-34.931m9.644M-3.208m71.184M-74.957m19.436M152.799M